3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
15
Breast Neoplasms
7
Sarcoma
5
Neoplasm Metastasis
4
Carcinoma, Ovarian Epithelial
4
Neoplasms
3
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multi-centric Castleman's Disease
2
Hodgkin Disease
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Osteosarcoma
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphadenopathy
1
Interventions
Gemcitabine
33
Cisplatin
22
pembrolizumab
21
Magnetic Resonance Spectroscopy
18
Specimen Handling
16
durvalumab
12
Mitomycin
10
enfortumab vedotin
9
avelumab
9
Nivolumab
9
Cystoscopy
9
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
7
Radiotherapy
6
Immunoglobulin G
6
Docetaxel
6
Disulfides
6
atezolizumab
5
Transurethral Resection of Bladder
5
Mitozytrex
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Standard of Care
4
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
liposomal doxorubicin
×
90 days
×
Clear all
No trials found.